Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Preventing the occurrence of graft-versus host disease through cell-based immunotherapy

FY 2016-17

Summary
Bone marrow transplantation can eradicate several blood cancers reported to be incurable by chemotherapy alone. A major side effect of this procedure is the development of chronic graft vs. host disease (cGvHD) which affects between 60 to 80% of long-term survivors. cGvHD is a serious inflammatory disorder which can target the skin, oral and genital mucosa, eyes, gut, liver, lungs, joints, and muscles. Currently, pharmacological agents that form the basis of cGvHD therapy are neither specific nor curative and patients are typically maintained under immunosuppressive regimens for several years to a lifetime. There is a growing body of evidence showing that B cells are involved in this pathology by the production of autoantibodies. Using mouse models, Dr Lesage's team has shown that a rare subset of T cells, termed DN T cells, can eliminate activated B cells directly within affected tissues, while sparing non-activated B cells.We therefore hypothesize that DN T cells can contribute to the prevention of cGvHD through the specific elimination of activated B cells. We aim to examine the cellular dynamics of B cells, DN T cells and autoantibodies in relation with cGvHD onset and severity in a cohort of bone marrow transplant recipients. This project will provide useful information to figure out if the data obtained in mouse models can be transposed to humans. This pilot study may help identify additional biomarkers of cGvHD severity and support the use of DN T cells as a therapeutic agent.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367230
Name
Lombard-Vadnais Felix
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Preventing the occurrence of graft-versus host disease through cell-based immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cellular Therapy; Double Negative T Cells; Graft-Versus-Host Disease; Immunology; Immunotherapy; Leukemia; Lymphocytes; Pre-Clinical Research; Regulatory Cells
Abstract
Bone marrow transplantation can eradicate several blood cancers reported to be incurable by chemotherapy alone. A major side effect of this procedure is the development of chronic graft vs. host disease (cGvHD) which affects between 60 to 80% of long-term survivors. cGvHD is a serious inflammatory disorder which can target the skin, oral and genital mucosa, eyes, gut, liver, lungs, joints, and muscles. Currently, pharmacological agents that form the basis of cGvHD therapy are neither specific nor curative and patients are typically maintained under immunosuppressive regimens for several years to a lifetime. There is a growing body of evidence showing that B cells are involved in this pathology by the production of autoantibodies. Using mouse models, Dr Lesage's team has shown that a rare subset of T cells, termed DN T cells, can eliminate activated B cells directly within affected tissues, while sparing non-activated B cells.We therefore hypothesize that DN T cells can contribute to the prevention of cGvHD through the specific elimination of activated B cells. We aim to examine the cellular dynamics of B cells, DN T cells and autoantibodies in relation with cGvHD onset and severity in a cohort of bone marrow transplant recipients. This project will provide useful information to figure out if the data obtained in mouse models can be transposed to humans. This pilot study may help identify additional biomarkers of cGvHD severity and support the use of DN T cells as a therapeutic agent.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lombard-Vadnais, Felix
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~